House committee to grill AbbVie CEO next month on suppressing Humira competition
AbbVie CEO Richard Gonzalez will be in the hot seat on May 18, again defending the company’s mammoth blockbuster drug Humira before the House Oversight Committee as competition for the world’s best-selling drug isn’t likely to hit American shores for about two years.
Oversight Committee Chairwoman Carolyn Maloney (D-NY) has been zeroing in on AbbVie for months now, even threatening to issue a subpoena last September for documents as part of her committee’s ongoing investigation into drug pricing practices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.